ID   EW-24
AC   CVCL_1215
SY   EW24; IARC-EW-24
DR   CLO; CLO_0009871
DR   ArrayExpress; E-MTAB-783
DR   ArrayExpress; E-MTAB-3610
DR   cancercelllines; CVCL_1215
DR   Cell_Model_Passport; SIDM00195
DR   ChEMBL-Cells; CHEMBL3308197
DR   ChEMBL-Targets; CHEMBL2366206
DR   Cosmic; 684069
DR   Cosmic; 949168
DR   Cosmic; 1995404
DR   Cosmic-CLP; 949168
DR   DepMap; ACH-002117
DR   EGA; EGAS00001000978
DR   GDSC; 949168
DR   GEO; GSM1669788
DR   IARC_TP53; 27168
DR   LINCS_LDP; LCL-1451
DR   PharmacoDB; EW24_357_2019
DR   PRIDE; PXD030304
DR   PubChem_Cell_line; CVCL_1215
DR   Wikidata; Q54833001
RX   DOI=10.5282/edoc.27750;
RX   PubMed=11423975;
RX   PubMed=20164919;
RX   PubMed=27397505;
RX   PubMed=30894373;
RX   PubMed=35839778;
CC   Part of: Cancer Dependency Map project (DepMap) (includes Cancer Cell Line Encyclopedia - CCLE).
CC   Part of: COSMIC cell lines project.
CC   Population: Caucasian.
CC   Microsatellite instability: Stable (MSS) (Sanger).
CC   Sequence variation: Gene fusion; HGNC; 3508; EWSR1 + HGNC; 3749; FLI1; Name(s)=EWSR1-FLI1, EWS-FLI1; Note=Type 1 fusion (Ex7/Ex6) (PubMed=11423975).
CC   Sequence variation: Mutation; HGNC; 8975; PIK3CA; Simple; p.His1047Arg (c.3140A>G); ClinVar=VCV000013652; Zygosity=Heterozygous (Cosmic-CLP; DepMap).
CC   Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Lys164Glu (c.490A>G); ClinVar=VCV000246416; Zygosity=Homozygous (Cosmic-CLP; DepMap).
CC   Omics: Deep exome analysis.
CC   Omics: Deep quantitative proteome analysis.
CC   Omics: DNA methylation analysis.
CC   Omics: SNP array analysis.
CC   Omics: Transcriptome analysis by microarray.
CC   Genome ancestry: African=0%; Native American=0%; East Asian, North=0%; East Asian, South=1.24%; South Asian=0%; European, North=60.48%; European, South=38.28% (PubMed=30894373).
ST   Source(s): Cosmic-CLP
ST   Amelogenin: X
ST   CSF1PO: 11,12
ST   D13S317: 14
ST   D16S539: 11
ST   D5S818: 12
ST   D7S820: 12,13
ST   TH01: 6,9.3
ST   TPOX: 10,12
ST   vWA: 15,16
DI   NCIt; C4817; Ewing sarcoma
DI   ORDO; Orphanet_319; Ewing sarcoma
OX   NCBI_TaxID=9606; ! Homo sapiens (Human)
SX   Sex unspecified
AG   Age unspecified
CA   Cancer cell line
DT   Created: 04-04-12; Last updated: 05-10-23; Version: 31
//
RX   DOI=10.5282/edoc.27750;
RA   Orth M.F.;
RT   "Systematic multi-omics profiling of Ewing sarcoma cell lines.";
RL   Thesis PhD (2021), Ludwig Maximilians University of Munich, Germany.
//
RX   PubMed=11423975; DOI=10.1038/sj.onc.1204437;
RA   Dauphinot L., De Oliveira C., Melot T., Sevenet N., Thomas V.,
RA   Weissman B.E., Delattre O.;
RT   "Analysis of the expression of cell cycle regulators in Ewing cell
RT   lines: EWS-FLI-1 modulates p57KIP2and c-Myc expression.";
RL   Oncogene 20:3258-3265(2001).
//
RX   PubMed=20164919; DOI=10.1038/nature08768;
RA   Bignell G.R., Greenman C.D., Davies H., Butler A.P., Edkins S.,
RA   Andrews J.M., Buck G., Chen L., Beare D., Latimer C., Widaa S.,
RA   Hinton J., Fahey C., Fu B.-Y., Swamy S., Dalgliesh G.L., Teh B.T.,
RA   Deloukas P., Yang F.-T., Campbell P.J., Futreal P.A., Stratton M.R.;
RT   "Signatures of mutation and selection in the cancer genome.";
RL   Nature 463:893-898(2010).
//
RX   PubMed=27397505; DOI=10.1016/j.cell.2016.06.017;
RA   Iorio F., Knijnenburg T.A., Vis D.J., Bignell G.R., Menden M.P.,
RA   Schubert M., Aben N., Goncalves E., Barthorpe S., Lightfoot H.,
RA   Cokelaer T., Greninger P., van Dyk E., Chang H., de Silva H., Heyn H.,
RA   Deng X.-M., Egan R.K., Liu Q.-S., Mironenko T., Mitropoulos X.,
RA   Richardson L., Wang J.-H., Zhang T.-H., Moran S., Sayols S.,
RA   Soleimani M., Tamborero D., Lopez-Bigas N., Ross-Macdonald P.,
RA   Esteller M., Gray N.S., Haber D.A., Stratton M.R., Benes C.H.,
RA   Wessels L.F.A., Saez-Rodriguez J., McDermott U., Garnett M.J.;
RT   "A landscape of pharmacogenomic interactions in cancer.";
RL   Cell 166:740-754(2016).
//
RX   PubMed=30894373; DOI=10.1158/0008-5472.CAN-18-2747;
RA   Dutil J., Chen Z.-H., Monteiro A.N.A., Teer J.K., Eschrich S.A.;
RT   "An interactive resource to probe genetic diversity and estimated
RT   ancestry in cancer cell lines.";
RL   Cancer Res. 79:1263-1273(2019).
//
RX   PubMed=35839778; DOI=10.1016/j.ccell.2022.06.010;
RA   Goncalves E., Poulos R.C., Cai Z.-X., Barthorpe S., Manda S.S., Lucas N.,
RA   Beck A., Bucio-Noble D., Dausmann M., Hall C., Hecker M., Koh J.,
RA   Lightfoot H., Mahboob S., Mali I., Morris J., Richardson L.,
RA   Seneviratne A.J., Shepherd R., Sykes E., Thomas F., Valentini S.,
RA   Williams S.G., Wu Y.-X., Xavier D., MacKenzie K.L., Hains P.G., Tully B.,
RA   Robinson P.J., Zhong Q., Garnett M.J., Reddel R.R.;
RT   "Pan-cancer proteomic map of 949 human cell lines.";
RL   Cancer Cell 40:835-849.e8(2022).
//